Yesterday, I wrote about the State of the Union speech, noting that the Biden proposal to expand the number of medicines to face negotiations was weirdly meaningless (Biden wants 500
I’m back -- 100% back -- from last week, where I was super-sick on Wednesday, rallied for a 6 a.m. flight the next day, and closed on my new home
I woke up this morning not feeling myself. Per Binax, I’m technically fine, COVID-wise, but I was still thrown for a loop. I’d intended to take tomorrow off -- there’s
There were three big takeaways from yesterday’s White House “listening session” on PBMs: The White House wants the David vs Goliath narrative. Of the five non-government speakers, four represented pharmacies.
There are two ways of looking at the ruling against AstraZeneca in its IRA lawsuit. (If you want to catch up quick on the basics, Bloomberg Law has you covered.)
Look, there’s not much going on today, so I won’t waste your time with a lot of fluff. In the absence of actual news, I’m paying close attention to potential
I mentioned yesterday that Merck had dropped its annual drug-price transparency report, warning that Merck’s numbers probably shouldn’t be extrapolated to the broader industry. After all, most companies don’t have
As is tradition, Merck is out as the first company to talk about 2023 list- and net-price changes across its portfolio. The company dropped its annual Pricing Action Transparency Report
So PBM reform is dead, according to the political press covering the government funding negotiations. STAT confirmed that fact with 11 different people, which is a feat. (Modern Healthcare, not
There’s a lot to go through today, but before I get started, I have a favor to ask: if you like what you’re reading, please forward it to a friend.